Form 13-F position report

SEELOS THERAPEUTICS INC

Reported by MORGAN STANLEY

SEEL CUSIP 81577F109 Manager CIK 0000895421

Reported 134,812 shares, down 827,111 (86.0%) from the prior quarter.

Reported value -87.2%; share count -86.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2021
Shares 134,812 Quarter-end amount reported
Reported value $325,000 Fair value at quarter end
Consecutive quarters held 6 Through Q3 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 325000
2021-12-31 554000
2022-03-31 308000
2022-06-30 257000
2022-09-30 331000
2022-12-31 238556
2023-03-31 241503
2023-06-30 455139
2023-09-30 91518
2023-12-31 0
2023-12-31 97527
2024-03-31 74504
2024-06-30 0
2024-06-30 13296
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for SEELOS THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -22,271 (-100.0%) 0 $0 2024-11-14
Q2 2024 New 22,271 +22,271 (0.0%) < 0.01% $13,296 2024-08-14
Q2 2024 Reduced 0 -126,064 (-100.0%) 0 $0 2024-08-14
Q1 2024 Added 126,064 +55,901 (79.7%) < 0.01% $74,504 2024-05-15
Q4 2023 New 70,163 +70,163 (0.0%) < 0.01% $97,527 2024-02-13
Q4 2023 Reduced 0 -497,380 (-100.0%) 0 $0 2024-02-13
Q3 2023 Added 497,380 +116,511 (30.6%) < 0.01% $91,518 2023-11-15
Q2 2023 Added 380,869 +31,471 (9.0%) < 0.01% $455,139 2023-08-14
Q1 2023 Reduced 349,398 -1,937 (-0.6%) < 0.01% $241,503 2023-05-15
Q4 2022 Added 351,335 +30,086 (9.4%) < 0.01% $238,556 2023-02-14
Q3 2022 Reduced 321,249 -57,487 (-15.2%) < 0.01% $331,000 2022-11-14
Q2 2022 Added 378,736 +10,783 (2.9%) < 0.01% $257,000 2022-08-15
Q1 2022 Added 367,953 +28,182 (8.3%) < 0.01% $308,000 2022-05-13
Q4 2021 Added 339,771 +204,959 (152.0%) < 0.01% $554,000 2022-02-14
Q3 2021 Reduced 134,812 -827,111 (-86.0%) < 0.01% $325,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

126 managers reported SEELOS THERAPEUTICS INC for Q3 2021.

Managers reporting SEELOS THERAPEUTICS INC in Q3 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 6,382,949 +1,041,138 < 0.01% $15,383,000 11 qtrs
VANGUARD GROUP INC Added 5,177,503 +377,180 < 0.01% $12,478,000 11 qtrs
Woodline Partners LP Added 4,379,396 +1,334,964 0.17% $10,554,000 3 qtrs
ACUTA CAPITAL PARTNERS LLC Unchanged 2,860,000 0 2.43% $6,893,000 3 qtrs
MANGROVE PARTNERS Unchanged 2,133,436 0 0.46% $5,142,000 3 qtrs
GENDELL JEFFREY L Added 1,859,635 +116,859 0.38% $4,481,000 3 qtrs
TWO SIGMA ADVISERS LP Added 1,771,100 +808,800 0.01% $4,268,000 5 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,721,677 +361,028 < 0.01% $4,149,000 12 qtrs
STATE STREET CORPORATION Added 1,579,863 +402,097 < 0.01% $3,807,000 2 qtrs
Uniplan Investment Counsel Inc Reduced 1,546,136 -3,403 0.23% $3,726,000 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2021
Filed
November 15, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
16,395
Shared
752
None
117,665

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.